The Eye Center offers a quick and painless cheek swab genetic test at our office, to determine your risk of Macular Degeneration. Call our office to schedule a few minutes out of your day for this simple and convenient test, billable under insurance.
Macula Risk® PGx is a combined prognostic and pharmacogenetic DNA test designed to determine a patient’s risk of progression to advanced Age-related Macular Degeneration (AMD) and aid in the selection of appropriate eye vitamin formulas for AMD based on his or her individual genetic risk profile.
AMD is a multifactorial disease involving the interplay of genetic, lifestyle, and environmental factors. Macula Risk PGx combines a patient’s current AMD status, genetic predisposition, and non-genetic risk factors to determine his or her 2, 5, and 10-year risk of developing advanced AMD, either geographic atrophy (GA) or choroidal neovascularization (CNV). The complexity underlying AMD onset and progression is reflected in the number and diversity of risk variables incorporated into the Macula Risk PGx test.
- AMD Status
- 15 Genetic Markers Across 12 AMD-
Non-Genetic Risk Factors
- Smoking History
Macula Risk PGx is most appropriate for patients with signs of disease (drusen and/or early, intermediate or advanced AMD) in at least one eye. It is only available through an eye care provider and uses a simple cheek swab to take a sample of a patient’s DNA. The test is covered by most insurance providers for patients with a diagnosis of AMD.
Pharmacogenetics is the science of how genetic variation affects an individual’s response to treatment. Pharmacogenetics is used to optimize therapeutic outcomes, determine the appropriate dose for a patient, and avoid harmful effects.
High-dose eye vitamins may be used to prevent progression from moderate to advanced AMD, and now also have pharmacogenetic indications.